Welcome to our dedicated page for Accenture Plc Ireland SEC filings (Ticker: ACN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Accenture’s 300-page SEC disclosures can bury the datapoints that move the stock—cloud revenue mix, new bookings, and how many consultants billable hours really grew. Finding those nuggets across a dense 10-K, multiple 10-Q updates, and rapid-fire 8-K acquisitions is the challenge every ACN investor faces.
Stock Titan solves that problem by marrying real-time EDGAR feeds with AI-powered summaries that translate complex language into clear takeaways. Need the next Accenture quarterly earnings report 10-Q filing? It lands here seconds after the SEC posts it, alongside a plain-English breakdown of segment margins and headcount trends. Curious about Accenture insider trading Form 4 transactions? Our dashboard flags executive buys and sells the moment they’re filed, complete with historical context.
Explore every disclosure type in one place:
- Annual report 10-K—see how consulting versus managed-services revenue shifts, with Accenture annual report 10-K simplified by AI.
- Quarterly 10-Q—track bookings momentum and free-cash-flow swings.
- 8-K material events—instant reads on acquisitions, leadership changes, or dividend announcements: Accenture 8-K material events explained.
- Proxy statement—understand Accenture proxy statement executive compensation without sifting through tables.
- Form 4—monitor Accenture executive stock transactions Form 4 in real time.
Whether you’re modeling cash flow, comparing segment profitability, or watching Accenture Form 4 insider transactions real-time, Stock Titan delivers the data and plain-language insight you need—no PDF spelunking required.
Jaime Ardila, a director of Accenture plc (ACN), received a grant of restricted share units (RSUs) on 08/15/2025 under the anti-dilution provisions of previously granted RSU awards to reflect Accenture's payment of a cash dividend. The Form 4 reports a non-derivative acquisition (transaction code A) with a reported price of $247.57. Following the reported transaction, Mr. Ardila beneficially owns 12,124 Class A ordinary shares directly. The filing was signed by an attorney-in-fact on 08/18/2025 and includes the explanatory remark that the RSUs were granted pursuant to anti-dilution provisions tied to a dividend.
Martin Brudermueller, an Accenture plc (ACN) director, received 5 restricted share units (RSUs) under anti-dilution provisions tied to prior RSU awards to reflect Accenture's cash dividend. The reported transaction shows an execution price reference of $247.57 per share and indicates 1,128 Class A ordinary shares beneficially owned by the reporting person following the grant. The Form 4 was submitted to disclose this non-derivative acquisition and clarifies the RSUs were granted specifically to adjust awards for the company dividend.
Alan C. Jope, a director of Accenture plc (ACN), reported an acquisition of 1,978 Class A ordinary shares on 08/15/2025. The shares were received as a grant of Restricted Share Units (RSUs) under anti-dilution provisions tied to a cash dividend; the report shows a deemed price of $247.57 per share. Following the transaction, Mr. Jope beneficially owns 1,978 shares directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing discloses a routine equity award adjustment rather than an open-market trade.
Accenture plc (ACN) Form 4: Director Nancy McKinstry was reported as acquiring restricted share units tied to Accenture Class A ordinary shares on 08/15/2025. The filing shows an acquisition (Code A) related to anti-dilution adjustments for previously granted RSU awards to reflect a cash dividend payment. The reported post-transaction beneficial ownership is 7,260 shares held directly. The transaction is documented with a reported per-share amount of $247.57 and was signed by an attorney-in-fact on behalf of the reporting person on 08/18/2025.
Jennifer Nason, a director of Accenture plc (ACN), reported an acquisition of 619 Class A ordinary shares through the grant of restricted share units (RSUs). The transaction date was 08/15/2025 and the form was filed with a signature dated 08/18/2025.
The RSUs were granted pursuant to the anti-dilution provisions of previously awarded RSU awards to reflect Accenture's payment of a cash dividend. The reported price associated with the RSU grant is $247.57 and ownership is reported as direct.
Paula A. Price, a director of Accenture plc (ACN), was granted 7,361 Class A ordinary shares as Restricted Share Units (RSUs) on 08/15/2025 at an indicated price of $247.57 per share. The Form 4 reports the acquisition code "A" and explains these RSUs were issued pursuant to anti-dilution provisions of previously granted awards to reflect Accenture's cash dividend. After the grant, Ms. Price beneficially owns 7,361 shares in direct form. The filing was signed by an attorney-in-fact on 08/18/2025.
Accenture plc (ACN): Director Venkata S. M. Renduchintala reported a Section 16 transaction dated 08/15/2025 showing acquisition of 3,703 Class A ordinary shares. The Form 4 indicates the shares were granted as Restricted Share Units (RSUs) under anti-dilution provisions tied to a cash dividend and lists a price of $247.57. The filing shows the shares are held directly and was signed on behalf of the reporting person by an attorney-in-fact on 08/18/2025.
Arun Sarin, a director of Accenture plc (ticker ACN), reported an acquisition on 08/15/2025 of 8,473 Class A ordinary shares via grant (Transaction Code A) of restricted share units. The grant was made pursuant to anti-dilution provisions tied to previously awarded RSUs to reflect Accenture's payment of a cash dividend. The reported price per share is $247.57, and the amount beneficially owned following the transaction is listed as 8,473 shares. The Form 4 was signed on behalf of Mr. Sarin by an attorney-in-fact on 08/18/2025.
Accenture plc (ACN) director Tracey Thomas received a grant of restricted share units (RSUs) tied to prior awards to reflect a cash dividend. The Form 4 shows a transaction dated 08/15/2025 recorded as an acquisition (code A) with a reference price of $247.57. Following the reported transaction the filing lists 8,573 Class A ordinary shares beneficially owned. The filing was signed on behalf of Tracey Thomas by an attorney-in-fact on 08/18/2025. The explanatory note states the grant resulted from anti-dilution provisions of previously granted RSU awards to reflect Accenture's dividend payment.
Masahiko Uotani, a director of Accenture plc (ACN), received a grant of 619 Class A ordinary shares recorded as restricted share units (RSUs) on 08/15/2025. The Form 4 reports the shares were issued pursuant to anti-dilution provisions tied to previously granted RSU awards to reflect Accenture's cash dividend. The reported transaction lists a price of $247.57 and shows 619 shares beneficially owned following the grant in a direct ownership form. The filing was signed by an attorney-in-fact on 08/18/2025. No other transactions, derivative holdings, or additional compensation details are disclosed in this Form 4.
FAQ
What is the current stock price of Accenture Plc Ireland (ACN)?
What is the market cap of Accenture Plc Ireland (ACN)?
